Results 61 to 70 of about 14,670 (186)

ADAM17 and its proteolytic targets in disease pathogenesis

The FEBS Journal, EarlyView.
ADAM17 as a multifunctional sheddase with contrasting roles across inflammatory, metabolic, cardiovascular, and neoplastic diseases. Through regulated activation by iRhom, iTAP/FRMD8, and tetraspanins, ADAM17 cleaves diverse membrane ligands and receptors, thereby promoting inflammation, fibrosis, obesity, insulin resistance, and tumor progression ...
Abdulbasit Amin, Marina Badenes
wiley   +1 more source

Lymphatic and angiogenic candidate genes predict the development of secondary lymphedema following breast cancer surgery. [PDF]

PLoS ONE, 2013
The purposes of this study were to evaluate for differences in phenotypic and genotypic characteristics in women who did and did not develop lymphedema (LE) following breast cancer treatment.
Christine Miaskowski, Marylin Dodd, Steven M Paul, Claudia West, Deborah Hamolsky, Gary Abrams, Bruce A Cooper, Charles Elboim, John Neuhaus, Brian L Schmidt, Betty Smoot, Bradley E Aouizerat   +11 more
doaj   +1 more source

Neuropilins: expression and roles in the epithelium

International Journal of Experimental Pathology, 2012
SummaryInitially found expressed in neuronal and then later in endothelial cells, it is well established that the transmembrane glycoproteins neuropilin‐1 (NRP1) and neuropilin‐2 (NRP2) play essential roles in axonal growth and guidance and in physiological and pathological angiogenesis.
Jonathan R L, Wild, Carolyn A, Staton, Keith, Chapple, Bernard M, Corfe   +3 more
openaire   +3 more sources

Nanoparticle‐Mediated Therapy for Glioma: Advances and Prospects

MedComm – Oncology, Volume 5, Issue 3, September 2026.
Various nanocarriers, including liposomes, dendrimers, exosomes and gold nanoparticles, are designed to penetrate the blood‐brain barrier and deliver chemotherapy, radiotherapy, immunotherapy, gene therapy, phototherapy, magnetic hyperthermia and sonodynamic therapy for glioma.
Wenqian Jiang, Jing Fei, Rangrang Fan, Haifeng Chen, Liangxue Zhou, Gang Guo   +5 more
wiley   +1 more source

New perspectives on VEGF signalling in Alzheimer's disease

Brain Pathology, Volume 36, Issue 5, September 2026.
Emery et al. bring together findings from recent multi‐omic studies, including single‐cell mRNA analysis of human post‐mortem brain tissue, and proteomic analysis of matched CSF and blood samples in large clinical studies. The authors present evidence of the involvement of altered VEGF signalling in vascular and immune dysfunction and neurodegeneration
Cherelle E. G. Emery, Seth Love, J. Scott Miners   +2 more
wiley   +1 more source

Semaphorins and Their Receptors in Hematological Malignancies

Frontiers in Oncology, 2019
While semaphorins were initially identified as axonal guidance cues for wiring the neural network, it was then recognized their wide relevance in tissue development and homeostasis.
Li Wei, Hongbo Li, Luca Tamagnone, Luca Tamagnone, Hua You, Hua You, Hua You   +6 more
doaj   +1 more source

Venom‐Derived Bioactive Peptides: From Toxins to Therapeutics

Advanced Therapeutics, Volume 9, Issue 8, August 2026.
Venomics → Target Identification → Peptide Optimization → Therapeutic Translation Bioactive venom peptides targeting ion channels, enzymes, and receptors drive the development of next‐generation precision therapeutics. ABSTRACT Venoms are complex biochemical mixtures composed of diverse bioactive components, including proteins, enzymes, small molecules,
Eldho Sabu, Othman Al Musaimi
wiley   +1 more source

Anifrolumab Treatment Leads to Rapid Reduction in Urinary Biomarkers of Intrarenal Inflammation in Lupus Nephritis: Results From the Phase 2 Randomized Trial

Arthritis &Rheumatology, Volume 78, Issue 8, Page 1692-1699, August 2026.
Objective Lupus nephritis (LN) is one of the most severe manifestations of systemic lupus erythematosus (SLE) and is partially driven by type I interferon signaling. Anifrolumab, an approved treatment for patients with SLE, has been investigated in a phase 2 trial in patients with LN receiving standard therapy (TULIP‐LN, ClinicalTrials.gov identifier ...
Andrea Fava, Michelle Petri, Patrick G. Gavin, Eszter Csomor, Philip Z. Brohawn, Daniel Muthas, Adam Platt, Catharina Lindholm, Nicola Ferrari   +8 more
wiley   +1 more source

Integrin α5β1 in pancreatic ductal adenocarcinoma: Tumour‒stroma crosstalk, hypoxia and therapeutic targeting

Clinical and Translational Medicine, Volume 16, Issue 8, August 2026.
ITGA5/integrin α5β1 promotes PDAC progression by integrating fibronectin‐dependent adhesion, hypoxia‐associated ECM remodelling, pancreatic stellate cell/cancer‐associated fibroblast activation, desmoplasia and tumour‒stroma crosstalk. These processes contribute to impaired drug delivery and therapeutic resistance.
Chenzhe Ma, Yingying Wang, Yumin Li
wiley   +1 more source

The Therapeutic Potential of H2S‐Releasing Platforms in Cardiovascular Applications

Journal of Biomedical Materials Research Part B: Applied Biomaterials, Volume 114, Issue 8, August 2026.
The Therapeutic Potential of H2S‐Releasing Platforms. ABSTRACT Once known as a toxic gas, hydrogen sulfide (H2S) is now making its way into many therapeutic applications. Similar to its other fellow endogenous gasotransmitters, nitric oxide and carbon monoxide, H2S is a small gas with a short half‐life, making it extremely capable of penetrating ...
Tia N. Shorter, Elizabeth J. Brisbois
wiley   +1 more source